BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

01 Mar 2021

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

BridgeBio lab — A researcher works in the lab of one of BridgeBio's portfolio companies • Source: BridgeBio Pharma Inc.

Since its inception in 2015, BridgeBio Pharma, Inc. has employed a hub-and-spoke business model similar to those used by Roivant Sciences Ltd. and Fortress Biotech Inc., putting its expertise and capital-raising prowess to work by simultaneously addressing multiple rare, monogenic diseases with no approved drugs. To date, the company has launched or acquired 17 companies (along with others still in stealth mode) and boasts a pipeline of 30-plus drug candidates, with one just approved and another with an action date in May or June.

In a wide-ranging interview with Cameron Turtle, senior vice president of portfolio management and corporate development, Scrip discussed the progress...